Supplementation With Lactococcus lactis LMG 27352: Lack of Beneficial Effects on Cardiometabolic Risk in Obese Patients Without Concomitant Dietary Intervention—A Randomized, Triple-Blind, Placebo-Controlled Clinical Trial

View at publisher
Authors: Melissa Aparecida Morais, Bianca Aparecida de Sousa, João Paulo Lima de Oliveira, Luíz Gustavo dos Santos, Yasmin Maria Borges Barolli Reis, Lívia Borges Rodrigues Silva, Maria Luiza Dutra Souza, Leandra Passarelli Castro e Souza, Isabela Coelho de Castro, Camila Maria de Melo, Andrezza Fernanda Santiago
Cited by: 0
References: 54

Abstract

Objective Recent evidence suggests that gut microbial imbalance may contribute to the pathogenesis of obesity-related metabolic disorders, including cardiovascular diseases. Although the underlying mechanisms remain incompletely understood, numerous studies have investigated the modulation of gut microbiota through probiotic supplementation as a potential preventive or therapeutic approach. This randomized, prospective, triple-blind, placebo-controlled clinical trial aimed to evaluate the effects of Lactococcus lactis, a probiotic with anti-inflammatory properties, on cardiometabolic risk factors associated with obesity.Method Fifty-two adults with elevated waist circumference and at least one additional metabolic alteration, such as elevated blood pressure, triglycerides, or glucose or reduced high-density lipoprotein cholesterol were recruited and randomly assigned to either a probiotic or placebo group (n = 26 each) for 90 days. During the study, 5 participants from the probiotic group withdrew, resulting in 21 participants for the probiotic group’s endpoint analyses. Neither group received guidance regarding food intake. Participants underwent assessments of anthropometry, body composition, dietary intake, and a range of biochemical markers.Results No significant improvements were observed on cardiometabolic risk parameters following L lactis LMG 27352 supplementation. Dietary analysis further revealed a significant rise in carbohydrate intake in both groups.Conclusions The findings of this study suggest limited clinical efficacy of L lactis LMG 27352 supplementation in metabolic disorders related to obesity under the conditions investigated. These results underscore the critical influence of dietary patterns, particularly sodium and carbohydrate intake, which may have modulated or counteracted any potential benefits of the probiotic strain.

Fields of Study & Subjects

Probiotics and Fermented Foods Gut microbiota and health Nutritional Studies and Diet

Publication details

Journal / source
Journal of the American Nutrition Association
Volume
45
Issue
5
Pages
451–463
Publication date
29 January 2026
Language
EN